Clinical experience with pramipexole in the treatment of restless legs syndrome

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 2, 2008, Pages 225-235

  Merlino, Giovanni ^a,b   Serafini, Anna ^a   Robiony, Francesca ^a   Valente, Mariarosaria ^a,b   Gigli, Gian Luigi ^a,b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Augmentation; Dopamine agonists; Periodic leg movements; Pramipexole; Rebound; Restless legs syndrome

Indexed keywords

CABERGOLINE; LEVODOPA; LISURIDE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; LOW DRUG DOSE; NAUSEA; NONHUMAN; POLYSOMNOGRAPHY; POSITIONAL VERTIGO; PREVALENCE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SOMNOLENCE;

ADULT; BENZOTHIAZOLES; DOPAMINE AGENTS; DOPAMINE AGONISTS; HUMANS; LEVODOPA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX;

EID: 39749198590     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.2.225     Document Type: Article

References (62)

1. American Academy of Sleep Medicine. International classification of sleep disorders. 2nd edition. Diagnostic and Coding Manual. American Academy of Sleep Medicine, Westchester, IL; 2005
2. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special conditions, and epidemiology. A report form the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19
3. Walters AS, Lebrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-32
4. Garcia-Borreguero D, Larrosa O, De La Llave Y, Granizo JJ, Allen R. Correlation between rating scales and sleep laboratori measurements in resstless legs sindrome. Sleep Med 2004;5:561-5
5. Zucconi M, Ferri R, Allen RP, et al. The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements La sleep (PLMS) and in wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med 2006;7:175-83
6. Merlino G, Valente M, Serafini A, Gigli GL. Restless legs syndrome: diagnosis, epidemiology, classification and consequences. Neurol Sci 2007;28(Suppl 1):S37-46
7. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS I study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-7
8. Walters AS, Ondo W, Dreykluft T, et al. Ropinitole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomised, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-23
9. Tan EK, Seah A, See SJ, Lim E, Wong MC, Koh KK. Restless legs syndrome in an Asian population: a study in Singapore. Mov Disord 2001;16:577-9
10. Sevim S, Dogu O, Camdeviren H, et al. Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology 2003;61:1562-9
11. Mizuno S, Miyaoka T, Inagaki T, Horiguchi J. Prevalence of restless legs syndrome in non-institutionalized Japanese elderly. Psychiatry Clin Neurosci 2005;59:461-5
12. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-92
13. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000;1:11-9
14. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997; 12:61-5
15. Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004;26:925-35
16. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001;16:1159-63
17. Aukerman MM, Aukerman D, Bayard M, Tuvider F, Thorp L, Bailey B. Exercise and restless legs syndrome: a randomised controlled trial. J Am Board Fam Med 2006;19:487-93
18. Chesson AL Jr, Whe M, Davila D, et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 1999;22:961-8
19. Hening W, Allern R, Early C, Kushida C, Picchietti D, Silber M. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 1999;22:970-99
20. Littner MR, Kushida C, Anderson WM, et al. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:557-9
21. Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:560-83
22. Oertel WH, Trenkwalder C, Zucconi M, et al. State of the art in restless legs syndrome therapy: practice recommendations for trearing restless legs syndrome. Mov Disord 2007;518:5466-75
23. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-13
24. Garcia-Borreguero D, Allen RP, Kohnen R, et al.; International Restless Legs Syndrome Study Group. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520-30
25. Garcia-Borreguero D, Kohnen R, Högl B, et al. Validation f the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 2007;8:520-30
26. Earley CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996;19:801-10
27. Trenkwalder C, Benes H, Grote L, et al.; Caldir Study Group. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multicentric, randomized, active controlled trial. Mov Disord 2007;22:696-703
28. Clemens S, Rye D, Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 2006;67:125-30
29. Merlino G, Dolso P, Canesin R, Cancelli I, Valente M, Gigli GL. The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial. Neuropsychobiology 2006; 54:195-200
30. Manconi M, Ferri R, Zucconi M, et al. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med 2007;8:491-7
31. Lin SC, Kaplan J, Burger CD, Fredrickson PA. Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin Proc 1998;73:497-500
32. Becker PM, Ondo W, Sharon D. Encouraging initial response of restless legs syndrome to pramipexole. Neurology 1998;51:1221-3
33. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000;7(Suppl 1):27-31
34. Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003;26:819-21
35. Stiasny-Kolster K, Oertel WH. Low-dose pramipexole in the management of restless legs syndrome. An open label trial. Neuropsychobiology 2004;50:65-70
36. Montplaisir J, Fantini ML, Desautels A, Michaud M, Petit D, Filipini D. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006; 13:1306-11
37. Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment Sleep Med 2002;3(Suppl 1):S23-5
38. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5:9-14
39. Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study-the PRELUDE study. Sleep Med 2006;7:407-17
40. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;67:1034-9
41. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007;22:213-9
42. Trenkwalder C, Stiasny-Kolster K, Kupsch A, et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 2006;21:1404-10
43. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005;9:185-200
44. Evans AH, Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord 2007;22:590-1
45. Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathological gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007;68:301-3
46. Quickfall J, Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 2007;13:535-6
47. Stiasny-Kolster K, Kohnen R, Möller JC, Trenkawalder C, Oettel WH. Validation of the "L-DOPA test" for diagnosis of restless legs syndrome. Mov Disord 2006;21:1333-9
48. Trenkwalder C, Stiasny K, Pollmächer T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995;18:681-8
49. Wetter TC, Stiasny-Kolster K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944-50
50. Stiasny K, Wetter TC, Winkelmann J, et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 2001; 56:1399-402
51. Stiasny K, Robbecke J, Schuler P, Oertel WH. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline-an open clinical trial. Sleep 2000;23:349-54
52. Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004;63:2272-9
53. Oertel WH, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology 2006;67:1040-6
54. Shaunak S, Wilkins A, Piling JB, Dick DJ. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry 1999;66:79-81
55. Zanetti R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinsod's disease. N Engl J Med 2007;356:39-46
56. Schade R, Anderohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38
57. Danoff SK, Grasso ME, Terry PB, Flynn JA. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 2001;120:313-6
58. Stiasny-Kolster K, Kohnen R, Schollmayer E, Möller JC, Oertel WH; Rotigotine SP 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004;19:1432-8
59. Oertel WH, Benes H, Garcia-Borreguero D, et al.; On Behalf of the Rotigotine SP 709 Study Group. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2007; In Press
60. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002;58:1019-24
61. Miranda M, Kagi M, Fabres L, et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology 2004;62:831-2
62. Saletu M, Anderer P, Hogl B, et al. Acute double-blind, placebo-controlled sleep laboratory and clincal follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. J Neural Transm 2003; 110:611-26